Literature DB >> 29054857

Diazepam Concurrently Increases the Frequency and Decreases the Amplitude of Transient Dopamine Release Events in the Nucleus Accumbens.

Scott A Schelp1, Zachary D Brodnik1, Dylan R Rakowski1, Katherine J Pultorak1, Asha T Sambells1, Rodrigo A España1, Erik B Oleson2.   

Abstract

Benzodiazepines are commonly prescribed anxiolytics that pose abuse liability in susceptible individuals. Although it is well established that all drugs of abuse increase brain dopamine levels, and benzodiazepines are allosteric modulators of the GABAA receptor, it remains unclear how they alter dopamine release. Using in vivo fast-scan cyclic voltammetry, we measured diazepam-induced changes in the frequency and amplitude of transient dopamine release events. We found that diazepam concurrently increases the frequency and decreases the amplitude of transient dopamine release events in the awake and freely moving rat. The time course during which diazepam altered the frequency and amplitude of dopamine release events diverged, with the decreased amplitude effect being shorter lived than the increase in frequency, but both showing similar rates of onset. We conclude that diazepam increases the frequency of accumbal dopamine release events by disinhibiting dopamine neurons, but also decreases their amplitude. We speculate that the modest abuse liability of benzodiazepines is due to their ability to decrease the amplitude of dopamine release events in addition to increasing their frequency.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29054857      PMCID: PMC5741045          DOI: 10.1124/jpet.117.241802

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  61 in total

1.  Overoxidation of carbon-fiber microelectrodes enhances dopamine adsorption and increases sensitivity.

Authors:  Michael L A V Heien; Paul E M Phillips; Garret D Stuber; Andrew T Seipel; R Mark Wightman
Journal:  Analyst       Date:  2003-11-11       Impact factor: 4.616

Review 2.  The benzodiazepine binding site of GABAA receptors.

Authors:  E Sigel; A Buhr
Journal:  Trends Pharmacol Sci       Date:  1997-11       Impact factor: 14.819

Review 3.  A brain on cannabinoids: the role of dopamine release in reward seeking.

Authors:  Erik B Oleson; Joseph F Cheer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

4.  Enhancement by flumazenil of dopamine release in the nucleus accumbens of rats repeatedly exposed to diazepam or imidazenil.

Authors:  C Motzo; M L Porceddu; L Dazzi; A Sanna; M Serra; G Biggio
Journal:  Psychopharmacology (Berl)       Date:  1997-05       Impact factor: 4.530

5.  Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam.

Authors:  D Bentué-Ferrer; J M Reymann; O Tribut; H Allain; E Vasar; M Bourin
Journal:  Eur Neuropsychopharmacol       Date:  2001-02       Impact factor: 4.600

Review 6.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

7.  Release of dopamine is reduced by diazepam more in the nucleus accumbens than in the caudate nucleus of conscious rats.

Authors:  R Invernizzi; L Pozzi; R Samanin
Journal:  Neuropharmacology       Date:  1991-06       Impact factor: 5.250

8.  Diazepam and cocaine potentiate brain stimulation reward in C57BL/6J mice.

Authors:  Carolin J Straub; William A Carlezon; Uwe Rudolph
Journal:  Behav Brain Res       Date:  2009-08-27       Impact factor: 3.332

9.  Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids.

Authors:  Dan P Covey; Kendra D Bunner; Douglas R Schuweiler; Joseph F Cheer; Paul A Garris
Journal:  Eur J Neurosci       Date:  2016-05-11       Impact factor: 3.386

10.  Rapid dopamine signaling in the nucleus accumbens during contingent and noncontingent cocaine administration.

Authors:  Garret D Stuber; Mitchell F Roitman; Paul E M Phillips; Regina M Carelli; R Mark Wightman
Journal:  Neuropsychopharmacology       Date:  2005-05       Impact factor: 7.853

View more
  8 in total

1.  Allopregnanolone Decreases Evoked Dopamine Release Differently in Rats by Sex and Estrous Stage.

Authors:  Ana Paula S Dornellas; Giovana C Macedo; Minna H McFarland; Alexander Gómez-A; Todd K O'Buckley; Claudio Da Cunha; A Leslie Morrow; Donita L Robinson
Journal:  Front Pharmacol       Date:  2021-01-14       Impact factor: 5.810

Review 2.  Dopamine, behavior, and addiction.

Authors:  Roy A Wise; Chloe J Jordan
Journal:  J Biomed Sci       Date:  2021-12-02       Impact factor: 8.410

3.  Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.

Authors:  Devan M Gomez; Thomas J Everett; Lindsey R Hamilton; Ajit Ranganath; Joseph F Cheer; Erik B Oleson
Journal:  Neuropharmacology       Date:  2020-10-25       Impact factor: 5.250

4.  A Transient Dopamine Signal Represents Avoidance Value and Causally Influences the Demand to Avoid.

Authors:  Katherine J Pultorak; Scott A Schelp; Dominic P Isaacs; Gregory Krzystyniak; Erik B Oleson
Journal:  eNeuro       Date:  2018-05-15

5.  Axonal mechanisms mediating γ-aminobutyric acid receptor type A (GABA-A) inhibition of striatal dopamine release.

Authors:  Paul F Kramer; Emily L Twedell; Jung Hoon Shin; Renshu Zhang; Zayd M Khaliq
Journal:  Elife       Date:  2020-09-01       Impact factor: 8.140

6.  Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin-evoked dopamine release in rats.

Authors:  Dominic P Isaacs; Ryan P Leman; Thomas J Everett; Hendrick Lopez-Beltran; Lindsey R Hamilton; Erik B Oleson
Journal:  Neuropsychopharmacol Rep       Date:  2020-09-15

Review 7.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

Review 8.  Axonal Modulation of Striatal Dopamine Release by Local γ-Aminobutyric Acid (GABA) Signalling.

Authors:  Bradley M Roberts; Emanuel F Lopes; Stephanie J Cragg
Journal:  Cells       Date:  2021-03-23       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.